Systematic Financial Management LP reduced its position in shares of Haemonetics Corporation (NYSE:HAE) by 1.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 43,495 shares of the medical instruments supplier’s stock after selling 695 shares during the period. Systematic Financial Management LP owned about 0.08% of Haemonetics Corporation worth $1,718,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its position in shares of Haemonetics Corporation by 9.3% during the 2nd quarter. Wells Fargo & Company MN now owns 2,788,122 shares of the medical instruments supplier’s stock worth $110,104,000 after purchasing an additional 238,294 shares during the last quarter. AMG National Trust Bank lifted its position in shares of Haemonetics Corporation by 8.4% during the 2nd quarter. AMG National Trust Bank now owns 18,892 shares of the medical instruments supplier’s stock worth $746,000 after purchasing an additional 1,463 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. lifted its position in shares of Haemonetics Corporation by 222.1% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 53,889 shares of the medical instruments supplier’s stock worth $2,128,000 after purchasing an additional 37,160 shares during the last quarter. Swiss National Bank lifted its position in shares of Haemonetics Corporation by 2.3% during the 2nd quarter. Swiss National Bank now owns 87,500 shares of the medical instruments supplier’s stock worth $3,455,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Pacad Investment Ltd. purchased a new stake in shares of Haemonetics Corporation during the 2nd quarter worth $174,000.

COPYRIGHT VIOLATION NOTICE: This story was published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/09/16/haemonetics-corporation-hae-stake-lessened-by-systematic-financial-management-lp.html.

HAE has been the subject of several recent analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $48.00 price objective on shares of Haemonetics Corporation in a research report on Thursday, July 27th. Zacks Investment Research cut shares of Haemonetics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, August 16th. TheStreet raised shares of Haemonetics Corporation from a “c” rating to a “b-” rating in a research report on Monday, August 7th. BidaskClub cut shares of Haemonetics Corporation from a “hold” rating to a “sell” rating in a research report on Friday, June 23rd. Finally, Barrington Research raised shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price objective for the company in a research report on Tuesday, August 8th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $40.71.

Shares of Haemonetics Corporation (HAE) opened at 42.29 on Friday. Haemonetics Corporation has a 12 month low of $32.76 and a 12 month high of $43.77. The stock has a market capitalization of $2.22 billion, a PE ratio of 549.22 and a beta of 0.89. The company has a 50-day moving average of $42.14 and a 200-day moving average of $40.82.

Haemonetics Corporation (NYSE:HAE) last announced its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.02. The company had revenue of $211.00 million during the quarter, compared to analyst estimates of $211.29 million. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. The firm’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period last year, the business earned $0.25 EPS. On average, equities research analysts expect that Haemonetics Corporation will post $1.60 EPS for the current fiscal year.

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.